Stockscreener 앱 받기
3.907
0.05%
0.007
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
What drives Lexeo Therapeutics Inc. stock priceFree Stock Market Return Analysis - Autocar Professional
Is Lexeo Therapeutics Inc. a good long term investmentBreakthrough profits - jammulinksnews.com
What analysts say about Lexeo Therapeutics Inc. stockFree Daily Trading Room Entry - Autocar Professional
Lexeo Therapeutics Inc. Stock Analysis and ForecastHigh-return market picks - jammulinksnews.com
Will Lexeo Therapeutics Inc. stock split in the near futureSafe and Smart Investment Picks - beatles.ru
Lexeo Therapeutics (NASDAQ:LXEO) & Organogenesis (NASDAQ:ORGO) Head to Head Analysis - Defense World
What analysts say about Lexeo Therapeutics Inc. stock outlookFree Investment Portfolio Suggestions - Newser
How high can Lexeo Therapeutics Inc. stock price go in 2025Safe and Smart Investment Picks - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
Why Lexeo Therapeutics Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
How Lexeo Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Lexeo Therapeutics soars 96% following March Fair Value signal By Investing.com - Investing.com South Africa
Lexeo Therapeutics soars 96% following March Fair Value signal - Investing.com
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target - Investing.com Nigeria
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target By Investing.com - Investing.com South Africa
Lexeo Therapeutics stock rises after FDA breakthrough designation By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Secures FDA Breakthrough Therapy Designation for LX2006, Shares Rise 8% in Pre-market Trade. - AInvest
Lexeo Therapeutics announces FDA Breakthrough Therapy Designation for LX2006 - TipRanks
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - Nasdaq
FDA grants breakthrough therapy designation to Lexeo’s FA treatment - Investing.com
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewswire
FDA Breakthrough: Lexeo's Gene Therapy Shows Promise in Fatal Rare Disease Treatment - Stock Titan
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan | ATNFW SEC FilingForm 8-K - Stock Titan
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan - Stock Titan
Lexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting - Investing.com
Lexeo Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Lexeo Therapeutics, Inc.(NasdaqGM: LXEO) dropped from Russell 2000 Growth Index - MarketScreener
Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases - Pharmafile
Lexeo to help launch spinout around RNA drugs for the heart - Yahoo Home
Bank of America Corp DE Trims Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics files to sell 41.63M shares of common stock for holders - MSN
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares - GuruFocus
Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders - MarketScreener
0.14%
0.32%
자본화:
|
볼륨(24시간):